Common use of Funding of Further Activities Clause in Contracts

Funding of Further Activities. (a) Prior to the commencement of any activities under Sections 7.1 and 7.2 above GENTA JAGO shall submit to KRYPTON * for such further activities which * shall be reasonably acceptable to KRYPTON. KRYPTON shall refund GENTA JAGO's * reasonably incurred by GENTA JAGO under Sections 7.1 and 7.2 above, including but not limited to costs, expenses and fees paid to Jago Pharma and third party contractors, by the payment of non-refundable development fees. Such further development costs shall be refunded by KRYPTON * upon receipt by KRYPTON of an invoice from GENTA JAGO or Jago Pharma AG. (b) Furthermore, KRYPTON shall be responsible, at its own cost, for the supply of all raw material including, but not limited to, the Active Ingredients required or necessary for, and all additional costs and expenses whatsoever arising out of or in connection with, the production of the Bio-Batches described in Section 7.2 above and all other costs associated with the use of facilities, technology transfer, equipment and analytical services.

Funding of Further Activities. (a) Prior to the commencement of any activities under Sections 7.1 and 7.2 above GENTA JAGO shall submit to KRYPTON * for such further activities which * budget and forecast shall be reasonably acceptable to KRYPTON. KRYPTON shall refund GENTA JAGO's * reasonably incurred by GENTA JAGO under Sections 7.1 and 7.2 above, including but not limited to costs, expenses and fees paid to Jago Pharma and third party contractors, by the payment of non-refundable development fees. Such further development costs shall be refunded by KRYPTON * upon receipt by KRYPTON of an invoice from GENTA JAGO or Jago Pharma AG. (b) Furthermore, KRYPTON shall be responsible, at its own cost, for the supply of all raw material including, but not limited to, the Active Ingredients required or necessary for, and all additional costs and expenses whatsoever arising out of or in connection with, the production of the Bio-Batches described in Section 7.2 above and all other costs associated with the use of facilities, technology transfer, equipment and analytical services.

Funding of Further Activities. (a) Prior to the commencement of any activities under Sections 7.1 and 7.2 above GENTA JAGO shall submit to KRYPTON * for such further activities which * shall be reasonably acceptable to KRYPTON. KRYPTON shall refund GENTA JAGO's * reasonably incurred by GENTA JAGO under Sections 7.1 and 7.2 above, including but not limited to costs, expenses and fees paid to Jago Pharma and third party contractors, by the payment of non-refundable development fees. Such further development costs shall be refunded by KRYPTON * upon receipt by KRYPTON of an invoice from GENTA JAGO or Jago Pharma AG. (b) Furthermore, KRYPTON shall be responsible, at its own cost, for the supply of all raw material including, but not limited to, the Active Ingredients required or necessary for, and all additional costs and expenses whatsoever arising out of or in connection with, the production of the Bio-Batches described in Section 7.2 ------------- * Confidential treatment requested. The redacted material has been separately filed wit the Commission. above and all other costs associated with the use of facilities, technology transfer, equipment and analytical services.

Funding of Further Activities. (a) Prior to the commencement of any activities under Sections 7.1 and 7.2 above GENTA JAGO shall submit to KRYPTON * for such further activities which * shall be reasonably acceptable to KRYPTON. KRYPTON shall refund GENTA JAGO's * reasonably incurred by GENTA JAGO under Sections 7.1 and 7.2 above, including but not limited to costs, expenses and fees paid to Jago Pharma and third party contractors, by the payment of non-refundable development fees. Such further development costs shall be refunded by KRYPTON * upon receipt by KRYPTON of an invoice from GENTA JAGO or Jago Pharma AG. (b) Furthermore, KRYPTON shall be responsible, at its own cost, for the supply of all raw material including, but not limited to, the Active Ingredients required or necessary for, and all additional costs and expenses whatsoever arising out of or in connection with, the production of the Bio-Batches described in Section 7.2 above and all other costs associated with the use of facilities, technology transfer, equipment and analytical services. ----------------- * Confidential treatment requested. The redacted material has been separately filed with the Commission.